Walmart halts H-1B visa offers amid Trump’s $100,000 fee increase - Bloomberg
Cencora, Inc. (NYSE:COR) President and CEO Robert P. Mauch sold 5,097 shares of common stock on October 20, 2025, for $1.66 million. The shares were sold at a price of $326.80, near the stock’s 52-week high of $325.70. The healthcare services provider, with a market capitalization of $63.7 billion, has delivered impressive returns, gaining over 45% year-to-date.
On the same day, Mauch also exercised options to acquire 3,763 shares of Cencora common stock at a price of $86.09, for a total value of $323956.
Following these transactions, Mauch directly owns 37,940 shares of Cencora.
The sale of shares was executed under a Rule 10b5-1 trading plan adopted November 15, 2024.
In other recent news, Cencora Inc. has reported its third-quarter earnings for 2025, surpassing Wall Street expectations. The company achieved an earnings per share of $4, beating the forecast of $3.84, and its revenue reached $80.7 billion, exceeding the anticipated $80.31 billion. Additionally, Moody’s has upgraded Cencora’s senior unsecured ratings to Baa1 from Baa2, reflecting the company’s strong business performance and robust prescription utilization trends. The outlook for Cencora was adjusted to stable, indicating confidence in its ongoing profitability growth.
Wells Fargo has also raised its price target for Cencora to $354 from $337, maintaining an Overweight rating. This adjustment was driven by strong core U.S. Healthcare performance, which helped offset weaker international results. These developments highlight Cencora’s continued strength in the market and its ability to exceed financial expectations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.